| Follow Us:

Biomedical : Innovation + Job News

136 Biomedical Articles | Page: | Show All

Phylogeny's world-class experts help bring important drugs to clinical trial

“Not many companies want to do what we do,” says Adel Mikhail, CEO of Phylogeny, Inc., in Columbus.

What Phylogeny does, according to Mikhail, is “help accelerate the discovery of new therapeutics and diagnostics for human health by enabling scientists to achieve excellence in functional genomic research.”

Phylogeny provides a range of expertise to help scientists at companies and institutes understand key biological processes about how genes function, he explains.

“Our clients in the corporate sector include most biotech companies and all the top-tier pharmaceutical companies,” he notes.

Scientists can outsource certain aspects of discovery research and development to Phylogeny instead of performing the studies in house themselves.

“Our experts perform the complicated research studies that are important for biological discovery,” he says. ”The type of research we provide requires a tremendous amount of experience and expertise and is difficult and costly to perform.”

Phylogeny was established in 2002 by Adel Mikhail and Craig Mello. Mello shared  the 2006 Nobel Prize in physiology for the discovery of RNAi, a long chain of nucleotide units that can turn genes off.

“By using RNAi, we explore the function of genes,” Mikhail explains. “RNAi can be used therapeutically to regulate genes involved in a disease process. It’s just one of the ways to study the biology of specific genes.”

Phylogeny’s scientists have been instrumental in bringing important drugs in the areas of cancer, obesity and osteoporosis to clinical trial.

According to Mikhail, their top three scientists have collectively authored more than 800 publications and can provide very quick insight to their clients.

The company has 21 employees, numerous contractors and part-time staff and received funding from Ohio’s Third Frontier initiative in both 2004 and 2010.

Source:  Adel Mikhail, Phylogeny, Inc.  
Writer:  Lynne Meyer

Nation's first Center for Environmental Genetics houses historic Fernald samples

Tucked away in Clifton on the medical side of UC's campus, researchers at the nation’s first Center for Environmental Genetics continue groundbreaking work, but with a new twist.

Their latest research game-changer involves decades worth of carefully documented biological samples now available for use by their peers all over the world.

If you have never heard of the Center for Environmental Genetics, you are not alone. Housed within the largest department of UC’s College of Medicine, the Department of Environmental Health, the CEG funds research on genetic (your personal script, already written at birth) and epigenetic (beyond genetics – how what you are exposed to today may impact your children’s genes and even further down the line) levels.

Conducting epigenetic studies can be particularly challenging, since multiple generations and variations of exposures are involved. That’s where a long-term human cohort study, started years ago as part of a $78 million settlement at the Fernald Feed Materials Processing Center, comes into play.

For years, residents around the Fernald plant had no idea that their neighbor was manufacturing uranium, not livestock feed. The long-term drama that ensued as the plant was shut down became the stuff of class action lawsuit history. What many residents wanted as much as restitution for their poisoned property was medical help and advice about how their homes might have made them, and their children, and their children’s children, sick.

So the settlement included an important stipulation: the largest medical monitoring project of its kind. From 1990 until 2008, residents were monitored and samples collected from all ages and all backgrounds. The cohort included multi-generational families, with sample collections coded to reflect their relationships.

At the end of the monitoring period, 160,000 biological samples from more than 9,500 participants are now stored at UC’s CEG. Not only can they be used to help examine and improve the lives of the participants and their families, but they can also be sent to researchers around the world who need stable, high-quality samples for their own genetic and epigenetic research.

Locally, doctors found evidence of increased cancer risk among residents, but they also were able to suggest opportunities that might help lower residents’ other risk factors, including the incidence of diabetes and heart disease.

As researchers and community members gathered on UC’s campus last month to discuss the decades-long project, participants and researchers agreed that, when done correctly and comprehensively, medical monitoring leads to both better health and better research.

Source: University of Cincinnati
Writer: Elissa Yancey

This story originally appeared in sister publication Soapbox.

Third Frontier funding helps company increase donor kidney odds, cleveland jobs

Quality Electrodynamics (QED) was one of the local recipients of Ohio Third Frontier funding for the development of an imaging system that will improve the way doctors evaluate whether a kidney is viable for donation.
 
The Cleveland-based company, working with the Cleveland Clinic’s Glickman Urological Institute, CWRU, Toshiba Medical Systems and Canon, received $1 million for the development of specialty MRI coils for imaging donor kidneys before transplant to determine viability.
 
Currently, potentially viable kidneys are sometimes rejected for transplant, or there are complications after transplant. This technology will improve the chances of success as well as reduce the number of kidneys that are thrown away.
 
“The program will result in a turnkey system of equipment, analysis software and clinical protocols which will be marketed to transplant centers on a worldwide basis,” says John L. Patrick, chief technical marketing officer for QED.

“Recipients of kidneys from deceased donors would benefit in several ways: Higher confidence level that the transplanted kidney can be viable and better knowledge of its condition; increase of transplanted kidneys by reducing the number of viable kidneys discarded will increase the number of patients able to benefit from transplantation.”
 
Patrick says the technology should be on the market in less than two years, depending on how clinical trials go. QED expects to begin hiring additional people for development of the technology in the next few months.

“In the proposal we stated that 38 jobs would be created at QED within 3 years,” says Patrick. “In fact, we believe that number to be quite conservative.”
 
Source: John L. Patrick
Writer: Karin Connelly

This story originally appeared in sister publication Fresh Water Cleveland.

Cleveland puts out welcome mat to the world

The growth of Cleveland into a major industrial powerhouse in the late 1800s and early 1900s was fueled by the labor and entrepreneurial skills of millions of immigrants. Arriving from Slovakia, Russia, Poland, Hungary, Italy, and Germany, they eagerly filled Cleveland jobs.

After nearly a decade of sliding population figures, Cleveland is now looking to recapture the momentum of those early days of robust economic growth by putting out a high-profile welcome mat to immigrants and others through the new Global Cleveland organization.

Global Cleveland focuses on regional economic development by attracting, welcoming and connecting newcomers, both economically and socially, to the many opportunities available throughout Greater Cleveland.

While the program officially launched in July, the Global Cleveland Welcome Hub will open this fall in the center of downtown Cleveland, according to Baiju Shah, chairman of the organization’s board.

“Global Cleveland will focus on all newcomers with active newcomer attraction initiatives to recruit individuals not currently residing in the Cleveland region,” he explains.

The target audience of newcomers includes immigrants, international students attending local universities and colleges, and “boomerangs”-- native Clevelanders returning to town.

The organization has four strategies: attraction, retention, connection and communication.

“We’ve discovered that many ex-Clevelanders have only limited information about both the economy and the region that was once their home,” Shah explains. “Once presented with the rich set of new opportunities here, they are pleasantly surprised and interested in learning more.”

Global Cleveland is developing a series of initiatives for attracting and retaining newcomers. Programs currently under way aim at showcasing job opportunities in health care, biomedical, IT and financial services.

“We’re also creating a resource directory to help newcomers get more quickly connected to the community,” he says.

The program has developed a host of partnerships with community organizations, agencies, universities and ethnic groups. “We will be establishing a network of welcome centers across the region,” Shah notes. “These centers will include information and resources to help newcomers get connected to both professional opportunities and to community resources throughout the region.”

Source:  Baiju Shah, Global Cleveland
Writer:  Lynne Meyer

NanoLogix growth fuels move to new R&D lab

The closing of a business incubator in Cincinnati has prompted NanoLogix, the Hubbard-based firm specializing in early detection of harmful microorganisms, to move its main R&D laboratory.

Instead of the Queen City, the lab will now be housed in the company's 4,000-square-foot headquarters building in Hubbard.

"It was an unanticipated move, but one that ultimately we're happy with," says Bret Barnhizer, NanoLogix's CEO.

For the past five years, NanoLogix's research and development was being done at the BioStart incubator in Cincinnati by a team of scientists. The company had even planned to expand that team, adding a two more scientists. That changed abruptly earlier this summer, when the site announced it would close by Sept. 30.  

According to Barnhizer, it didn't take long to come to the conclusion that consolidation was in the company's best interest.

"We looked around and there wasn't a deal with incentives like we had with BioStart. We had a phenomenal deal that gave us access to equipment and facilities we couldn't find elsewhere. But, we had this extra space in Hubbard. We happened to have just completed a clean-room production facility. And, if you needed to talk to one of our scientists, all you would have to do is walk down the hall," he says. "It turned out to be a wonderful move for us."

Now, all NanoLogix activities, from R&D to production and management, will be under one roof. The move comes at a time when the firm continues to validate their work on early detection of bacteria and other harmful microorganisms, including a 300-patient clinical trial being conducted at the University of Texas Health Science Center in Houston and work on new a new product line that could lead to early detection of tuberculosis.

According to Barnhizer, the work will continue seamlessly.

"We'll be scaling down our operations in Cincinnati about the same time we start working in Hubbard," he explains. "The move will help us save thousands of dollars per month in rent we won't have to pay, not to mention the efficiency savings involved."

With most of their lab staff opting to remain in Cincinnati, NanoLogix will also be hiring new scientists to man the new lab. The staff additions planned for Cincinnati will bring additional staff to the Hubbard site, he says.

"I won't denigrate the work our people in Cincinnati did for us, but this is a natural move. We're excited about the opportunities it affords us as we move forward," says Barnhizer.

Source: Bret T. Barnhizer, NanoLogix
Writer: Dave Malaska

VasoStar helping surgeons "tap" through deadly occlusions

The manual “tapping” of surgeons, intent on breaking through life-threatening occlusions, could soon be replaced by vibrating tip guidewires, says Stephanie Harrington, chief operating officer of VasoStar Inc. The company, a subsidiary of Frantz Medical Group in Mentor, is collaborating with Cleveland Clinic and Interplex Medical LLC of Milford, on the plaque-busting technology.

The company was formed in 2007 to “develop technology invented in Israel and brought to us through one of our clinician colleagues at Stanford University,” says Harrington. The vibrating guidewires let cardiologists open up totally blocked arteries much faster than the current manual method.

Lesions that have been there for some time, called chronic total occlusions, become calcified and very difficult to penetrate with a tiny guidewire only .014 in. diameter. Currently, the clinician is about 300 cm away from the lesion, outside of the patient’s leg, gently tapping to force the guidewire through the calcified surface.

“What we’ve done is increase the speed of the tapping and move that tapping source up near the point of the lesion,” says Harrington. The power source, a tiny electromagnetic engine, creates a high-frequency vibration. “This will allow patients with CTOs to be treated with interventional techniques versus invasive bypass surgery.”

The Ohio Third Frontier Commission, which supports the commercialization of products in the biomedical, medical imaging and sensors industries, recently awarded VasoStar $1 million to help develop the technology, which is still in the product-development stage. Harrington said clinical trials should start in about 18 months. The company employs four “fulltime equivalents” on loan from Frantz Medical and Harrington expects to add 12 to 15 positions over the next two years.  

Source: Stephanie A. S. Harrington, Frantz Medical Development Ltd.
Writer: Patrick G. Mahoney

UC's FETCH-LAB research helps pets, people

The idea of putting hearing aids on a dog may, to the uninitiated, seem like an extravagant splurge, the kind of move reserved for those with money to burn. But not to a team of researchers at the University of Cincinnati. It's one of several innovative projects designed to better understand how animals hear and communicate, with the hope of making the world more comfortable for both humans and our animal counterparts.

"This research has been going on for some time," says Pete Scheifele, PhD, head of UC's Facility for the Education and Testing of Canine Hearing and Lab Animal Bioacoustics (FETCH-LAB). "However, the noise impacts on animals have not been on the forefront, especially on animals that are domestic or captive."

Scheifele explains that, for years, vets and animal researchers paid little attention to hearing loss in animals such as domestic dogs. Owners who brought in their pets with concerns over hearing loss often saw vets use primitive tests, such as jingling keys or snapping and looking for reactions. When researchers started using pediatric hearing-test equipment to study dogs, however, an alarming trend surfaced: About 60 dog breeds showed a tendency toward congenital deafness, due in part to inbreeding.

"The awareness kind of shot up, because everyone's worried about having a deaf dog," he says. "It's had a domino effect."

Now, vets and researchers are working to identify causes of animal deafness, especially in service animals such as police and rescue dogs.

"Your job, perhaps your life, may depend on your working partner," Scheifele says.

FETCH-LAB scientists have also explored ways to combat excessive noise in places supposed to meet physical and mental needs. Kennels, for example, often have highly reflective walls and ceilings that bounce barks and yips into an annoying - and potentially harmful - cacophony.

"Kennels are made to be washed, not for hearing safety," he says.

The FETCH-LAB team recently installed sound-dampening panels at the League for Animal Welfare's kennel in Batavia, and is studying their effects on the sound levels and the health of both canine inhabitants and employees. And although Scheifele says testing is still underway, LFAW Director Mary Sue Bahr says that the panels are having a significant effect.

"Our goal for all of the dogs in our care is to provide a clean, healthy, friendly, stress-free environment for them,” says Bahr in a UC press release. "Having these sound panels helps us to fulfill that goal—and it’s also nice for our staff and volunteers. In reducing the sound levels, it helps them have a more enjoyable time here.”

Scieifele says FETCH-LAB also studies hearing and hearing loss in horses and marine animals, and is in the process of publishing a paper on optimizing aquarium design to provide stimulating - but not overwhelming - amounts of noise for captive inhabitants. The work, he explains, could both improve lives for animals, and could effect the way human hearing and noise control takes shape in the future.

"We often come back with information that's useful and say, 'we never thought about this in humans,'" he says. "We help the animals, and they help us."

Source: Pete Scheifele, University of Cincinnati
Writer: Matt Cunningham

This story originally appeared in sister publication Soapbox.

Heartlab's $18.4-million financing paves the way for faster growth

Cleveland HeartLab is moving quickly in the prevention and detection of cardiovascular disease. The company, spun off from the Cleveland Clinic in 2009, is a clinical laboratory and disease management startup that has developed a series of diagnostic tests for determining the risk of heart disease and stroke.
 
The company, which has grown from eight to 80 employees in two years, just completed an $18.4 million Series B financing round with Excel Venture Management and HealthCare Ventures, both out of Boston.
 
The investment will allow Cleveland HeartLab to expand -- both in employees and market acceptance. In addition to its current offerings, the company plans to introduce additional diagnostic tests in 2012. "The goal is to eliminate the threat of vascular inflammation," he says.
 
"The funding allows the company to double in size again," says Jake Orville, president and CEO. "And we've just committed to moving off [the Clinic's] campus to the Health Tech Corridor."
 
Orville predicts the company will double again in the next two years, adding positions in management, sales, marketing, and research and development. He attributes his company's growth to a talented, dedicated staff.

"We have the gift of really good novel technology," he says. "Combine that with really good people and a really good business plan."
 
Source: Jake Orville, HeartLab
Writer: Karin Connelly

This story originally appeared in sister publication Fresh Water Cleveland.

OSU College of Medicine lands $1.4-million grant to study brown algae's burn-healing power

In the world of medical research, the simplest answers can come from the strangest places. In the case of bacterial infections that take place after major burns, the answer may very well come from the sea.

Researchers at the Ohio State University College of Medicine, working with researchers in Norway, have landed a $1.4-million defense department grant to study the use of sea-produced brown algae and kelp to fight infections common to burns.

"The grant comes from the Department of Defense because of soldiers who suffer major burns in Afghanistan or Iraq," explains Dr. Chandan Sen, professor and vice chairman of research at OSUMC's Department of Surgery and one of the study's leaders. "Most of those burns get infected by bacteria like pseudomonas that thrive in desert areas. These bacteria form a biofilm, which defeats the kinds of antibiotics we typically use. They form a protective layer that antibiotics can't penetrate, and the infection gets worse. If you can't control the infection, ultimately it could lead to amputation or even death."

Though the genesis of the study was overseas casualties, the results of the study will have an impact worldwide. According to the Centers for Disease Control and Prevention, biofilms are linked to 60 percent of all chronic infections in the United States, even with its higher standard of health care. Pseudomonas itself was once responsible for more than half of all burn deaths in the U.S. Though that's no longer the case, the bacteria are living things, able to adapt. Over generations, they developed the ability to form the antibiotic-resistant biofilm.

The sea plants, Sen says, contain chemicals that have been shown to shut down the bacteria's ability to form that biofilm, once again making them vulnerable to common antibiotics.

"Once we can halt the production of the biofilm, we can kill the bacteria, and cure the infection," Sen points out. He doesn't find the answer to the biofilm problem odd, however.

"The fact of the matter is that bacteria are a part of nature and nature has its own way of controlling them," he says. Otherwise, bacteria would run rampant over the rest of the natural world.

"We humans can't produce the same chemicals, but nature has always had the answer," he says. "We're just looking to find a way to adapt nature's answer for use on humans."

The study, which has just begun and is expected to take a year to complete, includes researchers from OSU's Comprehensive Wound Care Center and the Dorothy M. Davis Heart and Lung Research Institute, along with their Norwegian colleagues.

Source: Dr. Chandan Sen, Ohio State University College of Medicine
Writer: Dave Malaska


First Biotech�s gene-creation technology could benefit medicine, agriculture, research

Athens-based startup First Biotech Inc. (FBTI) believes it’s found a better way to create new genes that could lead to new applications in medicine and other fields.

First Biotech produces and markets research reagents for a new smart DNA technology referred to as Unrestricted Mutagenesis and Cloning (URMAC). The technology was developed by the company’s founder, Louay Hallak. 

The technology replaces conventional subcloning techniques -- techniques that transfer a cloned DNA fragment from one vector to another -- with fast biochemical reactions that allow direct manipulation of large DNA sequences in an efficient, reliable and cost-effective way. The company has plans to establish a manufacturing and service operation in Ohio University’s Innovation Center.

FBTI, which registered as a C-corporation last year, is in the process of forming a management team in preparation for launch later this year.

“The main product,” says Hallak, “is fully developed and ready to go to market. We are starting with a professional team of experts in management, marketing and biotechnology . . . we will add new jobs as needed . . . FBTI will manufacture biochemical reagents, mainly for DNA mutagenesis and cloning,” Hallak says.

Hallak says the company’s new technique “will enable users to create new genes in shorter time, with high accuracy and less overall cost than the competition.”

URMAC has wide application in many fields, such as medicine. It can be used to create protein therapeutics and viral vectors; in research, it can “knock out” or change genes to help understand their function; and it can be used in agriculture, for crop engineering. 
 
FBTI has received pre-seed funding approval from TechGrowth Ohio, in addition to an earlier grant from TechColumbus. Hallak expects the new venture will achieve profitability within 12 to 18 months of launching.

Source: Louay Hallak, Founder, First Biotech Inc.
Writer: Patrick G. Mahoney

AtriCure continues to grow, snags Third Frontier grant

A $1-million Ohio Third Frontier award will help West Chester-based AtriCure develop and bring to market a next-generation version of its successful AtriClip.

The left atrial appendage is a saclike part of the heart that has internal peaks and valleys. During atrial fibrillation -- an abnormal rhythm of the heart -- the appendage can pool with blood, causing clots that can migrate to the brain and cause strokes.

The Gillinov-Cosgrove Left Atrial Appendage Exclusion system, which the FDA approved  last year for use in open-heart procedures, is designed as a more effective way to close blood flow between the appendage and the atria, thus eliminating the possibility of clots forming there. 

“Today, the clip is approved to be used during the open heart procedure,” says Julie Piton, VP Finance and Chief Financial Officer. The Third Frontier award will help fund development of a minimally invasive version of the device.

AtriCure was formed in 2000 to commercialize and market products developed by Enable Medical Technologies. In August 2005, AtriCure went public and subsequently purchased Enable.

Since then, the company has become a leading medical device company in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage. Cardiac ablation procedures are used to destroy small areas of the heart that may be cause abnormal heart rhythms.

The company boasted record revenues of $16.8 for the second quarter, with strong growth in international markets. Piton says the company has about 235 employees and has added about 10 in the last year.

Looking ahead, she says the company is poised to become “the first surgical company to get an atrial fibrillation indication” from the FDA.

What that means is that, if approved by the FDA, the company will be able to market its ablation products as a treatment for atrial fibrillation. Currently, they can only be marketed for the ablation of cardiac tissue.

“The only reason you would ablate cardiac tissue is to treat atrial fibrillation,” she says. “But we can’t market our outcomes and we can’t talk to physicians about atrial fibrillation, we can only talk about the technical attributes of our products.”

Source: Julie Piton, AtriCure
Writer: Gene Monteith


Promising artificial lung development can mean long-term mobility for patients

A team of researchers has developed an artificial lung that uses regular air, not pure oxygen, and is portable, marking a huge step forward for people with acute and chronic lung disease. The research is a result of collaboration between Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center

"The most significant finding is that we have demonstrated a small scale, prototype artificial lung," says Joseph A. Potkay, research assistant professor in CWRU's department of electrical engineering and computer science. "It represents a major leap forward toward a self-contained, portable or implantable device that would use ambient air, rather than oxygen cylinders, and would thus give patients full mobility." 

Current artificial lung systems require heavy tanks of oxygen, limiting patients' portability -- and they can be used only on patients at rest. Also, the lifetime of the system is measured in days. This new prototype is much smaller in size -- equivalent to a natural lung. 

"These results prove that constructing a device with features similar in size to those found in the natural lung can result in large improvements in efficiency over current alternatives, thereby enabling portable devices," says Potkay. "This technology will be used in portable heart lung machines and portable systems for the treatment of acute and chronic lung disease or as a bridge to transplant." 

Potkay and his team began developing the lung in early 2008 and will begin animal testing in two years. Human trials should begin in 10 years. The research was funded by the U.S. Department of Veterans Affairs. Lung disease affects over 200 million people worldwide.

Source: Joseph A. Potkay
Writer: Karin Connelly


OSU researchers mix old, new traditions in fight against brain cancer

New research from Ohio State University, a mix of Western medicine and Eastern herbal remedies, may finally give doctors a needed weapon in their fight against the most aggressive types of brain cancer.

In a study released on July 11, researchers at OSU's Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute determined a compound family called indirubins stop brain tumor cells from spreading to other areas of the brain.

Indirubins, which are found in a common Chinese herbal remedy, not only stop glioblastoma cells from migrating, the substance also retards other cells that help tumors form new blood vessels and grow, according to the study.

"Breakthroughs are in the eye of the beholder," says Dr. E. Antonio Chiocca, one of the study's principal investigators, "but time will tell. The key issue is that most patients with these kinds of tumors die because the cancer cells infiltrate the entire brain. We think indirubins are the answer for stopping that infiltration."

Glioblastomas are the most common and most aggressive form of brain tumors, with about 18,5000 cases diagnosed annually. The initial tumor can be treated through medication, chemotherapy or surgery, but the migration of cancer cells to other parts of the brain lead to a high mortality rate. Almost 13,000 death per year are attributed to the cancer. The median length of survival after diagnosis is roughly 15 months.

"We have pretty good therapies to keep the original tumor at bay, but there's nothing we currently have to stop the migration of those cells," Chiocca explains. "Combined with current therapies, we think indirubins can make a real difference."

The study, which appears in the current issue of "Cancer Research," was funded by the Esther L. Dardinger Endowment for Neuro-oncology and Neurosciences, the National Cancer Institute, the Jeffrey Thomas Hayden Foundation and the American Brain Tumor Association. It began by examining several classes of substances for their effect on tumor growth in mice.

Now, Chiocca says, the challenge is to continue the research until indirubins can be used in humans. For that, they'll need FDA approval. Another hurdle: Since indirubins have already been described chemically by other scientists, it isn't patentable.

"Without the promise of a patent, companies won't be interested in developing it further," he continues. To continue their work, they'll have to find a chemical variant of the substance that can be patented, or petition the National Institute of Health for funding.

Source:  E. Antonio Chiocca, OSU's Dardinger Center for Neurooncology and Neurosciences
Writer: Dave Malaska


PercuVision brings sight to tricky catheterizations

It's an unpleasant scene, but one that occurs daily in medical centers around the world. A person needs a urinary catheter. The nurse begins to place it. The catheter encounters an obstruction, so the nurse pulls it out and tries again. And again.
 
A Westerville company, PercuVision, has come up with a camera-aided alternative to make such a situation safer and more bearable. Called DirectVision, the technology is being used by nurses around the country.

"We added vision to urinary catheterization," says founder and CEO Errol Singh, who also practices urology at Capital Urology in Columbus. "As urologists, we have scopes in our hands that give us vision, and we use that primarily for diagnostic and other procedures, but the nurses unfortunately don't when they run into a difficult catheterization. (Now) the nurses can see what the problem is and are able to turn it and guide it."

PercuVision was founded in 2007, and DirectVison received FDA approval in August of 2009.

"It took time to make it through the commercialization process and get our supply chain established and so forth," says Singh. However, since then reception of the product "has been very very positive on a number of fronts. The technology is being embraced system wide in OhioHealth and we have the technology deployed in approximately six or seven sites around the country. We probably have another dozen or so sites that will be getting the technology soon."

OhioHealth, through the OhioHealth Research Institute, has supported Singh's work by facilitating clinical trials designed to confirm the device's effectiveness, he says. Other supporters include angel investors (who have funded the company to the tune of $6 million) and the Ohio Department of Development, which earlier this year awarded PercuVision a $1-million grant to develop the next generation of technology.

While the company currently employs 15 people -- 13 of whom are located in Ohio -- PercuVision plans to hire an additional 42 people in the next three to four years as the next generation of vision-guided catheters come to market.

Source: Errol Singh, PercuVision
Writer: Gene Monteith

NanoLogix says new research moves company a step closer to fast detection of Strep in moms, newborns

Hubbard-based NanoLogix on Monday announced new research confirming the company's ability to detect and identify Group B streptococcus in four to six hours -- 12 to 18 times more quickly than traditional detection methods, it says.

NanoLogix, which is awaiting FDA approval for its BioNanoPore and BioNanoFilter Quick Test technology, says in a news release that the research moves the company another step closer to making the technology available to women and newborns who are especially susceptible to strep infections.

According to NanoLogix, speed is of the essence when detecting Group B strep in mothers and infants. The release cites Centers for Disease Control statistics showing "25 percent of pregnant women may be colonized with Group B Strep. If colonized mothers give birth before antibiotics can be administered, the bacteria can be passed to the newborn and cause life-threatening blood infections, such as meningitis, sepsis, pneumonia or even still birth."

The new study was conducted at the University of Texas Health Science Center and published in the American Journal of Perinatology. 

Begun more than 20 years ago as Infectech, the company for years focused on research and other endeavors, including alternative energy. Re-christened NanoLogix in 2005, the company quickly refocused on rapid detection testing.

Last year, the company signed a multi-year contract with the U.S. Environmental Protection Agency to develop rapid testing for bacterial threats to drinking water.

The company has also built a 2,800-square foot manufacturing facility in Hubbard to localize work being done elsewhere.

Source: NanoLogix
136 Biomedical Articles | Page: | Show All
Share this page
0
Email
Print